Amplification and overexpression of mdm2 gene in ependymomas

Modern Pathology

Volumn 13, Issue 5, 2000, Pages 548-553

  Suzuki, Satoshi O ^a   Iwaki, Toru ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Ependymoma; Gene amplification; Immunohistochemistry; Mdm2; Oncogene; P53

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 12Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DNA DETERMINATION; EPENDYMOMA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION; TUMOR LOCALIZATION;

EID: 0034042177     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880095     Document Type: Article

References (45)

1. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-22.
2. Fink KL, Rushing EJ, Schold SJ, Nisen PD. Infrequency of p53 gene mutations in ependymomas. J Neurol Oncol 1996;27: 111-5.
3. Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol 1998;95:291-6.
4. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991;51:6202-5.
5. Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MS, Cogen PH. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A 1991;88:7825-9.
6. Tominaga T, Kayama T, Kumabe T, Sonoda Y, Yoshimoto T. Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis. Acta Neurochir (Wien) 1995;135: 163-70.
7. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
8. Cahilly SL, Yang FT, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987;13:235-44.
9. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
10. Cordon CC, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54: 794-9.
11. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
12. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 Mutation, and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
13. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki MS. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995;64:342-6.
14. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998;16:1603-10.
15. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-65.
16. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, et al. Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995;175:31-8.
17. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995;71:981-5.
18. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, et al. Mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 1995;4:93-7.
19. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-31.
20. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994;9:949-54.
21. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998;8:655-67.
22. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
23. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins W. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-303.
24. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-78.
25. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurol Oncol 1997;35:13-28.
26. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of mdm2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997;56:180-5.
27. Tong CYK, Ng H-K, Pang JCS, Hui ABY, Ji HCW, Lee JCK. Molecular genetic analysis of non-astrocytic gliomas. Histopathology 1999;34:331-41.
28. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. Berlin: Springer-Verlag; 1993.
29. Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, et al. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 1997;93:225-32.
30. Suzuki SO, Mizoguchi M, Iwaki T. Detection of SV40 T antigen genome in human gliomas. Brain Tumor Pathol 1997; 14:125-9.
31. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 1995;54:57-64.
32. Li Y, Chopp M, Powers C, Jiang N. Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res 1997;765:301-12.
33. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
34. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 auto-regulatory feedback loop. Genes Dev 1993;7:1126-32.
35. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
36. Kubbutat M, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997;387:299-303.
37. Buseo-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-23.
38. Landers JE, Haines DS, Strauss J, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9: 2745-50.
39. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
40. Jost CA, Marin MC, Kaelin WG. P73 is a human p53-related protein that can induce apoptosis. Nature 1997;389:191-4.
41. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999;18:3923-9.
42. Dobbelstein M, Wienzek S, Konig C, Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999;18:2101-6.
43. Ongkeko WM, Wang XQ, Siu WY, Lau A, Yamashita K, Harris AL, et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 1999;9:829-32.
44. Zeng XY, Chen LH, Jost CA, Maya R, Keller D, Wang XJ, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999;19:3257-66.
45. Loiseau H, Arsaut J, Demotes MJ. p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett 1999;263:173-6.